胰高血糖素样肽1 (GLP-1)在肥胖外科治疗中的作用研究进展
Progress in the Study of the Role of Glucagon-Like Peptide 1 (GLP-1) in the Surgical Treatment of Obesity
DOI: 10.12677/ACM.2023.132396, PDF,    国家自然科学基金支持
作者: 玉苏普江·伊明江, 依力汗·依明:新疆医科大学研究生学院,新疆 乌鲁木齐;买买提·依斯热依力:新疆维吾尔自治区人民医院微创,疝和腹壁外科,新疆 乌鲁木齐 ;新疆维吾尔自治区人民医院普外微创研究所,新疆 乌鲁木齐;艾克拜尔·艾力*:新疆医科大学研究生学院,新疆 乌鲁木齐;新疆维吾尔自治区人民医院微创,疝和腹壁外科,新疆 乌鲁木齐;新疆维吾尔自治区人民医院普外微创研究所,新疆 乌鲁木齐
关键词: 胰高血糖素样肽-1肥胖治疗Glucagon-Like Peptide-1 Obesity Treatment
摘要: 肥胖,传统上被定义为导致健康受损的身体脂肪过量,在临床实践中通常通过体重指数(身体质量指数)来评估,该指数被表示为以千克为单位的体重除以以平方米为单位的身高(kg/m2)的比率。尽管有大量的研究致力于理解肥胖和能量平衡的生物学,显而易见的是,现有的知识迄今为止对遏制肥胖流行几乎没有帮助,世界上没有一个地方能够幸免于这一现象。在过去半个世纪中,全球范围内肥胖患病率呈上升趋势,并已达到相当高的流行水平。由于大大增加了2型糖尿病、脂肪肝、高血压、心肌梗塞、阻塞性睡眠呼吸暂停等疾病以及一些癌症风险,从而导致生活质量下降,寿命下降,肥胖是一个重大的健康挑战。尤其是肥胖合并T2DM的患者比重在单纯肥胖人群中比例增大,使得肥胖与T2DM成为社会广泛关注的公共卫生问题。肥胖与T2DM密切相关,体重增加是T2DM的独立危险因素,而肥胖特别是中心性肥胖容易造成胰岛素抵抗,促使胰岛β细胞高负荷运转,从而使胰岛功能受损,导致T2DM的发生。肥胖与T2DM之间的关系相当复杂,最近比较热门的研究越来越重视肥胖与T2DM之间的分子、信号通路、免疫以及基因水平。故本文就肥胖及T2DM之间的分子、信号通路以及其近来在肥胖外科治疗中的作用作一简要综述。
Abstract: Obesity, traditionally defined as an excess of body fat leading to impaired health, is commonly as-sessed in clinical practice by the body mass index (BMI), expressed as the ratio of body weight in kilograms divided by height in square meters (kg/m2). Despite the large amount of research dedi-cated to understand the biology of obesity and energy balance, it is clear that the available knowledge has so far done little to curb the obesity epidemic, from which no part of the world is immune. The prevalence of obesity has been on the rise globally over the past half century and has reached considerable epidemic levels. Obesity is a major health challenge due to the greatly in-creased risk of diseases such as type 2 diabetes, fatty liver, hypertension, myocardial infarction, ob-structive sleep apnea, and some cancers, which lead to reduced quality of life and decreased life expectancy. In particular, the proportion of patients with obesity combined with T2DM has in-creased in the population with simple obesity, making obesity and T2DM a public health problem of wide social concern. Obesity and T2DM are closely related, and weight gain is an independent risk factor for T2DM, while obesity, especially central obesity, tends to cause insulin resistance and con-tribute to high islet β-cell load, thus impairing islet function and leading to the development of T2DM. The relationship between obesity and T2DM is quite complex, and recent more popular studies have increasingly focused on the molecular, signaling pathways, immune, and genetic levels between obesity and T2DM. Therefore, this paper provides a brief review of the molecular and sig-naling pathways between obesity and T2DM and their recent role in the surgical treatment of obe-sity.
文章引用:玉苏普江·伊明江, 依力汗·依明, 买买提·依斯热依力, 艾克拜尔·艾力. 胰高血糖素样肽1 (GLP-1)在肥胖外科治疗中的作用研究进展[J]. 临床医学进展, 2023, 13(2): 2811-2816. https://doi.org/10.12677/ACM.2023.132396

参考文献

[1] Holst, J.J. (2007) The Physiology of Glucagon-Like Peptide 1. Physiological Reviews, 87, 1409-1439. [Google Scholar] [CrossRef] [PubMed]
[2] Rajeev, S.P. and Wilding, J. (2016) GLP-1 as a Target for Ther-apeutic Intervention. Current Opinion in Pharmacology, 31, 44-49. [Google Scholar] [CrossRef] [PubMed]
[3] Aroda, V.R. (2018) A Review of GLP-1 Receptor Agonists: Evo-lution and Advancement, through the Lens of Randomised Controlled Trials. Diabetes, Obesity and Metabolism, 20, 22-33. [Google Scholar] [CrossRef] [PubMed]
[4] Prasad-Reddy, L. and Isaacs, D. (2015) A Clinical Review of GLP-1 Receptor Agonists: Efficacy and Safety in Diabetes and Beyond. Drugs in Context, 4, Article ID: 212283. [Google Scholar] [CrossRef] [PubMed]
[5] Reed, J., Kanamarlapudi, V. and Bain, S. (2018) Mechanism of Cardio-vascular Disease Benefit of Glucagon-Like Peptide 1 Agonists. Cardiovascular Endocrinology & Metabolism, 7, 18-23. [Google Scholar] [CrossRef
[6] Graaf, C., Donnelly, D., Wootten, D., et al. (2016) Gluca-gon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. Pharmaco-logical Reviews, 68, 954-1013. [Google Scholar] [CrossRef] [PubMed]
[7] Zhao, X., Wang, M., Wen, Z., et al. (2021) GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects. Frontiers in Endocrinology (Lausanne), 12, Article ID: 721135. [Google Scholar] [CrossRef] [PubMed]
[8] Camilleri, M. (2015) Peripheral Mechanisms in Appetite Regula-tion. Gastroenterology, 148, 1219-1233. [Google Scholar] [CrossRef] [PubMed]
[9] Berthoud, H.R. and Zheng, H. (2012) Modulation of Taste Re-sponsiveness and Food Preference by Obesity and Weight Loss. Physiology & Behavior, 107, 527-532. [Google Scholar] [CrossRef] [PubMed]
[10] Joyner, M.A., Gearhardt, A.N. and White, M.A. (2015) Food Craving as a Mediator between Addictive-Like Eating and Problematic Eating Outcomes. Eating Behaviors, 19, 98-101. [Google Scholar] [CrossRef] [PubMed]
[11] Gearhardt, A.N., Rizk, M.T. and Treat, T.A. (2014) The Associ-ation of Food Characteristics and Individual Differences with Ratings of Craving and Liking. Appetite, 79, 166-173. [Google Scholar] [CrossRef] [PubMed]
[12] Chao, A.M., Wadden, T.A., Tronieri, J.S., et al. (2019) Effects of Addictive-Like Eating Behaviors on Weight Loss with Behavioral Obesity Treatment. Journal of Behavioral Medicine, 42, 246-255. [Google Scholar] [CrossRef] [PubMed]
[13] Janse Van Vuuren, M.A., Strodl, E., White, K.M. and Lockie, P.D. (2018) Emotional Food Cravings Predicts Poor Short-Term Weight Loss Following Laparoscopic Sleeve Gastrectomy. British Journal of Health Psychology, 23, 532-543. [Google Scholar] [CrossRef] [PubMed]
[14] Horowitz, M., Flint, A., Jones, K.L., et al. (2012) Effect of the Once-Daily Human GLP-1 Analogue Liraglutide on Appetite, Energy Intake, Energy Expenditure and Gastric Emptying in Type 2 Diabetes. Diabetes Research and Clinical Practice, 97, 258-266. [Google Scholar] [CrossRef] [PubMed]
[15] Koliaki, C. and Doupis, J. (2011) Incretin-Based Therapy: A Powerful and Promising Weapon in the Treatment of Type 2 Diabetes Mellitus. Diabetes Therapy, 2, 101-121. [Google Scholar] [CrossRef] [PubMed]
[16] Secher, A., Jelsing, J., Baquero, A.F., Hecksher-Sørensen, J., et al. (2014) The Arcuate Nucleus Mediates GLP-1 Receptor Agonist Liraglutide-Dependent Weight Loss. Journal of Clin-ical Investigation, 124, 4473-4488. [Google Scholar] [CrossRef
[17] Eissele, R., Göke, R., Willemer, S., et al. (1992) Glucagon-Like Peptide-1 Cells in the Gastrointestinal Tract and Pancreas of Rat, Pig and Man. European Journal of Clinical Investigation, 22, 283-291. [Google Scholar] [CrossRef] [PubMed]
[18] Diakogiannaki, E., Gribble, F.M. and Reimann, F. (2012) Nutrient Detection by Incretin Hormone Secreting Cells. Physiology & Behavior, 106, 387-393. [Google Scholar] [CrossRef] [PubMed]
[19] Nauck, M.A. and Meier, J.J. (2016) The Incretin Effect in Healthy Individuals and Those with Type 2 Diabetes: Physiology, Pathophysiology, and Response to Therapeutic Inter-ventions. The Lancet Diabetes & Endocrinology, 4, 525-536. [Google Scholar] [CrossRef
[20] Drucker, D.J. and Nauck, M.A. (2006) The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes. The Lancet, 368, 1696-1705. [Google Scholar] [CrossRef
[21] Caruso, I., Cignarelli, A. and Giorgino, F. (2019) Heteroge-neity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials. Trends in Endocrinology and Metab-olism, 30, 578-589. [Google Scholar] [CrossRef] [PubMed]
[22] Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R. and Creutzfeldt, W. (1993) Preserved Incretin Activity of Glucagon-Like Peptide 1 [7-36 amide] but Not of Synthetic Human Gastric Inhibitory Polypeptide in Patients with Type-2 Diabetes Mellitus. Journal of Clinical Investigation, 91, 301-307. [Google Scholar] [CrossRef
[23] Nauck, M.A., Kleine, N., Orskov, C., Holst, J.J., Willms, B. and Creutzfeldt, W. (1993) Normalization of Fasting Hyperglycaemia by Exogenous Glucagon-Like Peptide 1 (7-36 Amide) in Type 2 (Non-Insulin-Dependent) Diabetic Patients. Diabetologia, 36, 741-744. [Google Scholar] [CrossRef
[24] Nauck, M.A., Heimesaat, M.M., Behle, K., Holst, J.J., Nauck, M.S., Ritzel, R., Hüfner, M. and Schmiegel, W.H. (2002) Effects of glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experi-ments in Healthy Volunteers. The Journal of Clinical Endocrinology & Metabolism, 87, 1239-1246. [Google Scholar] [CrossRef] [PubMed]
[25] McLean, B.A., Wong, C.K., Campbell, J.E., Hodson, D.J., Trapp, S. and Drucker, D.J. (2021) Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation. Endocrine Reviews, 42, 101-132. [Google Scholar] [CrossRef] [PubMed]
[26] Heimbürger, S.M., Bergmann, N.C., Augustin, R., Gasbjerg, L.S., Christensen, M.B. and Knop, F.K. (2020) Glucose-Dependent Insulinotropic Polypeptide (GIP) and Cardiovascular Disease. Peptides, 125, Article ID: 170174. [Google Scholar] [CrossRef] [PubMed]
[27] Mingrone, G., Panunzi, S., De Gaetano, A., et al. (2012) Bari-atric Surgery versus Conventional Medical Therapy for Type 2 Diabetes. The New England Journal of Medicine, 366, 1577-1585. [Google Scholar] [CrossRef
[28] Mingrone, G., Panunzi, S., De Gaetano, A., et al. (2021) Metabolic Surgery versus Conventional Medical Therapy in Patients with Type 2 Diabetes: 10-Year Follow-Up of an Open-Label, Single-Centre, Randomised Controlled Trial. The Lancet, 397, 293-304. [Google Scholar] [CrossRef
[29] Wren, A.M., Small, C.J., Abbott, C.R., et al. (2001) Ghrelin Causes Hyperphagia and Obesity in Rats. Diabetes, 50, 2540-2547. [Google Scholar] [CrossRef] [PubMed]
[30] Casajoana, A., Pujol, J., Garcia, A., et al. (2017) Predictive Value of Gut Peptides in T2D Remission: Randomized Controlled Trial Comparing Metabolic Gastric Bypass, Sleeve Gastrec-tomy and Greater Curvature Plication. Obesity Surgery, 27, 2235-2245. [Google Scholar] [CrossRef] [PubMed]
[31] Nosso, G., Griffo, E., Cotugno, M., et al. (2016) Comparative Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Glucose Homeostasis and Incretin Hormones in Obese Type 2 Diabetic Patients: A One-Year Prospective Study. Hormone and Metabolic Research, 48, 312-317. [Google Scholar] [CrossRef] [PubMed]
[32] Stefater, M.A., Sandoval, D.A., Chambers, A.P., Wilson-Perez, H.E. and Hofmann, S.M. (2011) Sleeve Gastrectomy in Rats Improves Postprandial Lipid Clearance by Reducing Intestinal Triglyceride Secretion. Gastroenterology, 141, 939-949.e1-4. [Google Scholar] [CrossRef] [PubMed]
[33] Nannipieri, M., Baldi, S., Mari, A., et al. (2013) Roux-en-Y Gastric Bypass and Sleeve Gastrectomy: Mechanisms of Diabetes Remission and Role of Gut Hormones. The Journal of Clinical Endocrinology & Metabolism, 98, 4391-4399. [Google Scholar] [CrossRef] [PubMed]
[34] Jiménez, A., Mari, A., Casamitjana, R., Lacy, A., Ferrannini, E. and Vi-dal, J. (2014) GLP-1 and Glucose Tolerance after Sleeve Gastrectomy in Morbidly Obese Subjects with Type 2 Diabetes. Diabetes, 63, 3372-3377. [Google Scholar] [CrossRef] [PubMed]
[35] Aung, L., Lee, W.-J., Chen, S.C., et al. (2016) Bariatric Surgery for Pa-tients with Early-Onset vs Late-Onset Type 2 Diabetes. JAMA Surgery, 151, 798-805. [Google Scholar] [CrossRef] [PubMed]